Halyard Health, Inc. (NYSE:HYH)‘s stock had its “buy” rating reaffirmed by equities research analysts at Stifel Nicolaus in a research note issued to investors on Thursday. They currently have a $45.00 target price on the medical instruments supplier’s stock. Stifel Nicolaus’ target price would indicate a potential downside of 2.49% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. TheStreet raised Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Wednesday, July 12th. BidaskClub downgraded Halyard Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 8th. Deutsche Bank AG raised their price objective on Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Halyard Health presently has an average rating of “Buy” and a consensus price target of $42.25.

Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.14. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The firm had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. During the same period last year, the business posted $0.45 EPS. Halyard Health’s quarterly revenue was down .2% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “Halyard Health, Inc. (HYH) Rating Reiterated by Stifel Nicolaus” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/21/halyard-health-inc-hyh-rating-reiterated-by-stifel-nicolaus.html.

A number of institutional investors have recently added to or reduced their stakes in the business. CENTRAL TRUST Co increased its position in Halyard Health by 1.0% during the first quarter. CENTRAL TRUST Co now owns 2,643 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 25 shares in the last quarter. Meadow Creek Investment Management LLC increased its position in Halyard Health by 1.1% during the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 28 shares in the last quarter. Glen Harbor Capital Management LLC increased its position in Halyard Health by 1.1% during the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 34 shares in the last quarter. Commonwealth Equity Services Inc increased its position in Halyard Health by 0.4% during the second quarter. Commonwealth Equity Services Inc now owns 11,342 shares of the medical instruments supplier’s stock worth $369,000 after buying an additional 48 shares in the last quarter. Finally, IFP Advisors Inc increased its position in Halyard Health by 1.9% during the second quarter. IFP Advisors Inc now owns 3,141 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 58 shares in the last quarter. 91.02% of the stock is owned by institutional investors.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.